Logo image of LSB

LAKESHORE BIOPHARMA CO LTD (LSB) Stock Fundamental Analysis

NASDAQ:LSB - Nasdaq - KYG9845F2080 - Common Stock - Currency: USD

1.02  -0.03 (-2.86%)

Fundamental Rating

2

LSB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 555 industry peers in the Biotechnology industry. LSB has a bad profitability rating. Also its financial health evaluation is rather negative. LSB has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

LSB had negative earnings in the past year.
LSB Yearly Net Income VS EBIT VS OCF VS FCFLSB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

LSB's Return On Assets of -30.26% is fine compared to the rest of the industry. LSB outperforms 65.77% of its industry peers.
With a Return On Equity value of -71.94%, LSB perfoms like the industry average, outperforming 53.51% of the companies in the same industry.
Industry RankSector Rank
ROA -30.26%
ROE -71.94%
ROIC N/A
ROA(3y)-15.14%
ROA(5y)N/A
ROE(3y)-37.76%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LSB Yearly ROA, ROE, ROICLSB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Gross Margin of LSB (79.48%) is better than 85.23% of its industry peers.
LSB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LSB Yearly Profit, Operating, Gross MarginsLSB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 50 -50

More info and screens

2

2. Health

2.1 Basic Checks

LSB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LSB has more shares outstanding
Compared to 1 year ago, LSB has an improved debt to assets ratio.
LSB Yearly Shares OutstandingLSB Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M 25M
LSB Yearly Total Debt VS Total AssetsLSB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

LSB has an Altman-Z score of -2.29. This is a bad value and indicates that LSB is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of LSB (-2.29) is comparable to the rest of the industry.
LSB has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.13, LSB is not doing good in the industry: 66.85% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z -2.29
ROIC/WACCN/A
WACC5.61%
LSB Yearly LT Debt VS Equity VS FCFLSB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 1.17 indicates that LSB should not have too much problems paying its short term obligations.
With a Current ratio value of 1.17, LSB is not doing good in the industry: 85.77% of the companies in the same industry are doing better.
A Quick Ratio of 0.90 indicates that LSB may have some problems paying its short term obligations.
The Quick ratio of LSB (0.90) is worse than 88.11% of its industry peers.
Industry RankSector Rank
Current Ratio 1.17
Quick Ratio 0.9
LSB Yearly Current Assets VS Current LiabilitesLSB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

1

3. Growth

3.1 Past

LSB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.08%.
Looking at the last year, LSB shows a very negative growth in Revenue. The Revenue has decreased by -16.56% in the last year.
EPS 1Y (TTM)-33.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%105.76%
Revenue 1Y (TTM)-16.56%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%284.18%

3.2 Future

Based on estimates for the next years, LSB will show a very strong growth in Earnings Per Share. The EPS will grow by 42.50% on average per year.
LSB is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -10.61% yearly.
EPS Next Y45.9%
EPS Next 2Y42.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year32.68%
Revenue Next 2Y52.65%
Revenue Next 3Y-24.94%
Revenue Next 5Y-10.61%

3.3 Evolution

LSB Yearly Revenue VS EstimatesLSB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 500M 1B
LSB Yearly EPS VS EstimatesLSB Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 0 -10 -20 -30

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LSB. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 7.16, the valuation of LSB can be described as very cheap.
97.48% of the companies in the same industry are more expensive than LSB, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.76, LSB is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 7.16
LSB Price Earnings VS Forward Price EarningsLSB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LSB Per share dataLSB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
LSB's earnings are expected to grow with 42.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.5%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LSB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LAKESHORE BIOPHARMA CO LTD

NASDAQ:LSB (7/2/2025, 8:00:00 PM)

1.02

-0.03 (-2.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-15 2024-08-15/bmo
Earnings (Next)N/A N/A
Inst Owners6.86%
Inst Owner ChangeN/A
Ins Owners29.8%
Ins Owner ChangeN/A
Market Cap19.46M
Analysts80
Price Target31.62 (3000%)
Short Float %0.23%
Short Ratio0.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.16
P/S 0.24
P/FCF N/A
P/OCF N/A
P/B 0.23
P/tB 0.26
EV/EBITDA N/A
EPS(TTM)-5.66
EYN/A
EPS(NY)0.14
Fwd EY13.96%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS4.2
BVpS4.41
TBVpS3.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.26%
ROE -71.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.48%
FCFM N/A
ROA(3y)-15.14%
ROA(5y)N/A
ROE(3y)-37.76%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.17
Quick Ratio 0.9
Altman-Z -2.29
F-ScoreN/A
WACC5.61%
ROIC/WACCN/A
Cap/Depr(3y)406.64%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%105.76%
EPS Next Y45.9%
EPS Next 2Y42.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-16.56%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%284.18%
Revenue Next Year32.68%
Revenue Next 2Y52.65%
Revenue Next 3Y-24.94%
Revenue Next 5Y-10.61%
EBIT growth 1Y-106.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year97.28%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-41.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.8%
OCF growth 3YN/A
OCF growth 5YN/A